COX7B Is a New Prognostic Biomarker and Correlates with Tumor Immunity in Esophageal Carcinoma

Figure 3

The survival analysis of COX7B in ESCA patients. (a) The OS and (b) survival distributions for PFS were plotted for patients with high and low COX7B expression in ESCA. (c) Estimating the likelihood of survival at 1, 3, and 5 years in ESCA patients using a ROC curve that changes over time.

(a)

(b)

(c)